Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

[1]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[2]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[3]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[4]  John P H Wilding,et al.  Liraglutide in the treatment of obesity , 2014, Expert opinion on biological therapy.

[5]  A. Canbay,et al.  Extrahepatic complications of nonalcoholic fatty liver disease , 2014, Hepatology.

[6]  Rachel M. Brown,et al.  Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial , 2013, BMJ Open.

[7]  V. Ratziu,et al.  Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.

[8]  S. Gough,et al.  Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program , 2013, Alimentary pharmacology & therapeutics.

[9]  N. Chalasani,et al.  Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .

[10]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[11]  B. Neuschwander‐Tetri,et al.  Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[12]  S. E. Park,et al.  Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice , 2012, PloS one.

[13]  D. Sorescu,et al.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[14]  M. Davies,et al.  Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[16]  M. Vivarelli,et al.  Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[17]  F. Anania,et al.  GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy , 2011, PloS one.

[18]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[19]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[20]  Z. Halpern,et al.  Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. , 2011, Journal of hepatology.

[21]  N. Chalasani,et al.  Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series , 2010, The American Journal of Gastroenterology.

[22]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[23]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[24]  F. Anania,et al.  Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway , 2010, Hepatology.

[25]  G. Corazza,et al.  Anti-Goblet Cell Antibodies for the Diagnosis of Autoimmune Enteropathy? , 2009, The American Journal of Gastroenterology.

[26]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[27]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[28]  D. Klonoff,et al.  Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. , 2007, Clinical therapeutics.

[29]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[30]  R. Heine,et al.  Incretin mimetics as a novel therapeutic option for hepatic steatosis , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[31]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[32]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[33]  L. B. Knudsen,et al.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. , 2000, Journal of medicinal chemistry.